InflaRx (IFRX) and The Competition Head-To-Head Analysis

InflaRx (NASDAQ:IFRX) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare InflaRx to similar companies based on the strength of its risk, profitability, valuation, earnings, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares InflaRx and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-32.04%	-27.33%
InflaRx Competitors	-12,359.35%	-203.09%	-30.93%

Volatility & Risk

InflaRx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, InflaRx’s peers have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Institutional & Insider Ownership

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares InflaRx and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InflaRx	$30,000.00	-$51.63 million	-3.36
InflaRx Competitors	$698.09 million	$10.43 million	-15.42

InflaRx’s peers have higher revenue and earnings than InflaRx. InflaRx is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for InflaRx and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1	2	5	1	2.67
InflaRx Competitors	9846	15128	45476	1589	2.54

InflaRx currently has a consensus target price of $7.43, indicating a potential upside of 467.07%. As a group, “Biotechnology” companies have a potential upside of 98.46%. Given InflaRx’s stronger consensus rating and higher probable upside, research analysts plainly believe InflaRx is more favorable than its peers.

Summary

InflaRx beats its peers on 8 of the 12 factors compared.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.